U.S. FDA approves Gilead's Biktarvy triple HIV drug

Mail Online -

Mail Online—Feb 7 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc's once-daily triple-combination tablet for...

U.S. FDA approves Gilead triple HIV drug, rival files lawsuit. (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc's once-daily triple-combination tablet for treatment of HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.